1. Immunology/Inflammation
    GPCR/G Protein
    Anti-infection
  2. CCR
    HIV

Maraviroc (Synonyms: UK-427857; Selzentry; Celsentri)

Cat. No.: HY-13004 Purity: 99.34%
Data Sheet SDS Handling Instructions

Maraviroc is a selective CCR5 antagonist, inhibits MIP-1α (IC50, 3.3 nM), MIP-1β (IC50, 7.2 nM), and RANTES (IC50, 5.2 nM) binding to cell membrane preparations of CCR5-expressing HEK-293.

For research use only. We do not sell to patients.
Maraviroc Chemical Structure

Maraviroc Chemical Structure

CAS No. : 376348-65-1

Size Price Stock Quantity
1 mg   Get quote  
5 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products

    Maraviroc purchased from MCE. Usage Cited in: Front Pharmacol. 2017 May 3;8:230.

    Inhibition of total and phosphorylation levels of CCR5, PKC δ, and p38 in MIP-1β-induced U937 cells by WTD. Cells are pretreated with PMA for 48 h and then incubated with or without WTD or MVC for 2 h. Subsequently, cells are stimulated with MIP-1β (25 nM). After 10 min of stimulation, cells are collected to detect total and phosphorylated (p) CCR5 (A), PKC δ (B), and p38 (C) by western blotting.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Maraviroc is a selective CCR5 antagonist, inhibits MIP-1α (IC50, 3.3 nM), MIP-1β (IC50, 7.2 nM), and RANTES (IC50, 5.2 nM) binding to cell membrane preparations of CCR5-expressing HEK-293.

    IC50 & Target

    IC50: 3.3 nM (MIP-1α), 7.2 nM (MIP-1β), 5.2 nM (RANTES)[1]

    In Vitro

    Maraviroc is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity. Maraviroc inhibits the downstream event of chemokine-induced intracellular calcium redistribution, with IC50s ranging from 7 to 30 nM obtained against MIP-1β, MIP-1α and RANTES. Maraviroc is active (IC90) at low nanomolar concentrations against HIV-1 Ba-L (a lab-adapted R5 strain) when measured in a 5-day antiviral assay using either isolated multiple (pooled) donor PBMC (IC90, 3.1 nM), single-donor PBMC (IC90, 1.8 nM) or PM-1 cells (IC90, 1.1 nM)[1].

    In Vivo

    Clearance values are moderate to high in both rat and dog species following i.v. administration (74 and 21 mL/min/kg, respectively). Maraviroc also has a moderate volume of distribution in both species (4.3 to 6.5 liters/kg). The half-life values of maraviroc are 0.9 h in the rat and 2.3 h in the dog. Following oral administration (2 mg/kg) to the dog, the Cmax(256 ng/mL) occurs 1.5 h. post-dose, and the bioavailability is 40%. For the rat, investigation of the concentrations obtain in the portal vein following oral administration indicated that approximately 30% of the administered dose is absorbed from the intestinal tract[1]. In the DSS/TNBS colitis and in the transfer model, Maraviroc attenuates development of intestinal inflammation by selectively reducing the recruitment of CCR5 bearing leukocytes[2]

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00821535 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) Infection February 2009 Phase 1
    NCT00864474 ViiV Healthcare|Pfizer CCR5-tropic HIV-1 Infection March 2010
    NCT01348308 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Pfizer HIV-1 Infection|AIDS September 2011 Phase 3
    NCT00935480 Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Merck Sharp & Dohme Corp.|Abbott HIV Infections October 2010 Phase 3
    NCT00821535 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) Infection February 2009 Phase 1
    NCT00864474 ViiV Healthcare|Pfizer CCR5-tropic HIV-1 Infection March 2010
    NCT01348308 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Pfizer HIV-1 Infection|AIDS September 2011 Phase 3
    NCT00935480 Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Merck Sharp & Dohme Corp.|Abbott HIV Infections October 2010 Phase 3
    NCT02881762 University of Maryland|ViiV Healthcare Hepatitis C|Human Immunodeficiency Virus June 1, 2017 Phase 4
    NCT00775294 University of North Carolina, Chapel Hill|Pfizer HIV/AIDS May 2008 Phase 1
    NCT01428986 National Center for Global Health and Medicine, Japan HIV Infections|AIDS November 2009
    NCT00948753 Abramson Cancer Center of the University of Pennsylvania Graft-versus-host Disease|Hematopoietic Stem Cell Transplantation June 2009 Phase 1|Phase 2
    NCT01133210 Washington University School of Medicine|Pfizer Hypertriglyceridemia January 2011 Phase 1
    NCT01980329 Johns Hopkins University Cytochrome P450 CYP3A5 Enzyme Polymorphism|Healthy Subjects|Pharmacokinetics of Maraviroc January 2013 Phase 1
    NCT00944541 French National Agency for Research on AIDS and Viral Hepatitis|Pfizer HIV Infection|HIV Infections September 2009 Phase 2
    NCT01389063 S.F.L. van Lelyveld|UMC Utrecht Endothelial Dysfunction January 2012 Phase 4
    NCT02934022 Southern California Institute for Research and Education|Pfizer HIV Infection June 2012
    NCT01627717 Centre hospitalier de l'Université de Montréal (CHUM)|Université de Montréal|McGill University Health Center|Toronto General Hospital Healthy June 2012 Phase 1
    NCT02167451 Children's Hospital Medical Center, Cincinnati Diagnoses That Require Stem Cell Transplant|Graft Versus Host Disease (GVHD) July 2014 Phase 1|Phase 2
    NCT02159027 University of Hawaii|ViiV Healthcare|University of Puerto Rico AIDS Dementia Complex May 2015 Phase 2|Phase 3
    NCT00791700 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) April 2009 Phase 2
    NCT01449006 Bruce Brew|ViiV Healthcare|St Vincent's Hospital, Sydney Human Immunodeficiency Virus (HIV)|HIV Associated Neurocognitive Disorders (HAND) October 2011 Phase 4
    NCT01056874 ViiV Healthcare|Pfizer Healthy|HIV Infections March 2010 Phase 1
    NCT01190293 St Stephens Aids Trust HIV Infection January 2010 Phase 4
    NCT00709111 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections January 2009
    NCT01420523 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Merck Sharp & Dohme Corp.|ViiV Healthcare Human Immunodeficiency Virus|Lipohypertrophy December 2011 Phase 2
    NCT03172026 University of California, Los Angeles|Burke Rehabilitation Hospital Stroke July 2017 Phase 2|Phase 3
    NCT00982878 Imperial College London|Pfizer HIV Infections September 2009 Phase 1
    NCT00884858 Ospedale L. Sacco – Polo Universitario HIV Infections April 2009 Phase 4
    NCT00665561 ViiV Healthcare|Pfizer Human Immunodeficiency Virus March 31, 2008
    NCT00719823 ViiV Healthcare|Pfizer Human Immunodeficiency Virus Type 1 August 2008 Phase 3
    NCT01276236 University of California, San Francisco|Pfizer|ViiV Healthcare Kaposi's Sarcoma February 2011
    NCT01597895 ViiV Healthcare|Pfizer Healthy July 2012 Phase 1
    NCT01866267 St. Hope Foundation|GlaxoSmithKline Human Immunodeficiency Virus|AIDS January 2013 Phase 4
    NCT01894776 Ottawa Hospital Research Institute|Pfizer HIV Infection|HIV-1 Infection|Mycobacterium Avium Complex (MAC) June 2013 Phase 1
    NCT02990312 University of Maryland Hiv|Kidney Transplant|HIV Reservoir|CCR5 May 1, 2017 Phase 4
    NCT01235013 Hospital Clinic of Barcelona HIV-1 Infection Phase 4
    NCT00735072 University of California, San Francisco|Pfizer|amfAR, The Foundation for AIDS Research|Stanford University|Case Western Reserve University|Rush University HIV Infection September 2008 Phase 4
    NCT00853840 ViiV Healthcare|Pfizer AIDS April 2008 Phase 4
    NCT00666705 ViiV Healthcare|Pfizer Healthy February 2008 Phase 4
    NCT00875368 S.F.L. van Lelyveld|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Leiden University Medical Center|Onze Lieve Vrouwe Gasthuis|Slotervaart Hospital|Rijnstate Hospital|Pfizer|UMC Utrecht HIV Infections February 2009 Phase 4
    NCT01348763 Imperial College London HIV October 2011 Phase 1
    NCT00703586 Rockefeller University|Aaron Diamond AIDS Research Center|Pfizer HIV Infections September 2007 Phase 1
    NCT02625207 ViiV Healthcare|Pfizer Healthy Subjects November 6, 2015 Phase 1
    NCT02346084 International Partnership for Microbicides, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH) HIV/AIDS January 2015 Phase 1
    NCT00827112 ViiV Healthcare|Pfizer Human Immunodeficiency Virus-1 March 2009 Phase 2
    NCT02799888 Affiliated Hospital to Academy of Military Medical Sciences Graft-versus-host Disease|Hematopoietic Stem Cell Transplantation April 2014 Phase 2
    NCT00981318 Rodwick, Barry M., M.D.|Abbott HIV Infections|Acquired Immunodeficiency Syndrome December 2009 Phase 4
    NCT01068873 Temple University|Abbott|Pfizer HIV Infections April 2010 Phase 4
    NCT00782301 ViiV Healthcare|Pfizer Hepatitis B|Human Immunodeficiency Virus|Hepatitis C, Chronic March 2009 Phase 4
    NCT01896921 University of Maryland HIV September 2013 Phase 3
    NCT01049204 St Stephens Aids Trust HIV Infections July 2009 Phase 4
    NCT01384682 Kirby Institute|ViiV Healthcare|Pfizer HIV August 2011 Phase 4
    NCT00993148 Northwestern University|Pfizer|Tibotec, Inc HIV-1 Infection|HIV Infections May 2010 Phase 2
    NCT00771823 St Stephens Aids Trust HIV Infections May 2008 Phase 1
    NCT02778204 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections May 1, 2017 Phase 1
    NCT00966329 Germans Trias i Pujol Hospital HIV|HIV Infections October 2009 Phase 4
    NCT01367210 Catholic University of the Sacred Heart HIV Infection June 2011 Phase 4
    NCT01140412 ViiV Healthcare|Pfizer Healthy July 2010 Phase 1
    NCT01291459 Association Pour la Recherche en Infectiologie HIV September 2011 Phase 2
    NCT00426660 ViiV Healthcare HIV Infections February 2007 Phase 3
    NCT01242579 International Partnership for Microbicides, Inc. HIV Infections January 2011 Phase 1
    NCT02134717 Kevin F. Gibson|University of Pittsburgh Sarcoidosis January 2014
    NCT02480894 Bristol-Myers Squibb HIV/AIDS July 2015 Phase 1
    NCT00992654 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) November 2009
    NCT01719627 Fundacio Lluita Contra la SIDA HIV October 2012 Phase 1
    NCT03178084 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal HIV/AIDS October 15, 2014 Phase 3
    NCT01749566 Emory University HIV December 2012 Phase 1
    NCT00427934 Pfizer Arthritis, Rheumatoid February 2007 Phase 2
    NCT00987948 University of Hawaii|Pfizer HIV Infections January 2010 Phase 2
    NCT01345630 ViiV Healthcare|Pfizer HIV-1 September 2011 Phase 3
    NCT01290211 ViiV Healthcare|Pfizer Healthy April 2011 Phase 1
    NCT01327547 ViiV Healthcare|Pfizer HIV Coinfection May 2011 Phase 4
    NCT00870363 University of California, Davis HIV Infections April 2009 Phase 4
    NCT01363037 International Partnership for Microbicides, Inc. HIV Infections November 2011 Phase 1
    NCT00988780 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Witwatersrand, South Africa|Case Western Reserve University|The Wistar Institute|University of Pennsylvania Immune Reconstitution Inflammatory Syndrome|HIV|HIV Infections December 2009
    NCT01597648 GlaxoSmithKline Infection, Human Immunodeficiency Virus I November 2011 Phase 1
    NCT01013987 The Huesped Foundation|Pfizer HIV-1 Adults Patients|AIDS|Triple Class Failure February 2010 Phase 4
    NCT00478231 ViiV Healthcare|Pfizer Acquired Immunodeficiency Syndrome|HIV Infection July 2007 Phase 3
    NCT02039323 University of North Carolina, Chapel Hill Healthy Adult Females February 2014 Phase 1
    NCT03129113 Medical Research Council|University College, London is the trial sponsor|MRCCTU at UCL is coordinating the trial Hepatic Steatosis|HIV-1-infection August 2017 Phase 2|Phase 3
    NCT00808002 Germans Trias i Pujol Hospital HIV Infections February 2009 Phase 3
    NCT01585753 Kirby Institute Cardiovascular Disease June 2012
    NCT00844519 University of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections January 2010 Phase 3
    NCT00850395 ViiV Healthcare|Pfizer HIV-1 July 2009
    NCT01680536 St Stephens Aids Trust HIV November 2012 Phase 4
    NCT02333045 Emory University HIV January 2015
    NCT01785810 Abramson Cancer Center of the University of Pennsylvania Hematologic Malignancy Requiring Allogeneic Stem-cell Transplantation. February 2013 Phase 2
    NCT00795444 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Pfizer HIV-1 March 2008 Phase 2
    NCT01204905 University of Maryland|Merck Sharp & Dohme Corp. HIV Infections September 2010
    NCT00634959 ViiV Healthcare|Pfizer HIV July 2003 Phase 2
    NCT01637233 Kirby Institute HIV-1 Infection June 2012
    NCT01533272 Hospital Clinic of Barcelona HIV Infection February 2012 Phase 4
    NCT02486510 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal HIV-1 Infection July 2012 Early Phase 1
    NCT00925756 California Collaborative Treatment Group|University of California, Los Angeles|University of Southern California|Pfizer|California HIV/AIDS Research Program HIV Infections June 2009 Phase 4
    NCT00717067 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) Infection July 2008 Phase 4
    NCT01060618 Asociacion para el Estudio de las Enfermedades Infecciosas HIV Infections May 2009 Phase 2|Phase 3
    NCT02519777 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2016 Phase 4
    NCT00098722 ViiV Healthcare|Pfizer HIV Infections December 2004 Phase 2|Phase 3
    NCT00098306 ViiV Healthcare|Pfizer HIV Infections November 2004 Phase 2|Phase 3
    NCT00098748 ViiV Healthcare|Pfizer HIV Infections November 2004 Phase 2|Phase 3
    NCT01736813 National Center for Tumor Diseases, Heidelberg|University Hospital Heidelberg Colorectal Cancer|Neoplasm Metastasis|Liver Metastases November 2012
    NCT01329783 ViiV Healthcare|Copenhagen HIV Programme|Pfizer HIV|AIDS April 2007 Phase 4
    NCT01154673 University of Toronto|St. Michael's Hospital, Toronto|Maple Leaf Medical Clinic Acute HIV Infection November 2011 Phase 2|Phase 3
    NCT00783484 Pfizer Healthy Volunteers October 2008 Phase 1
    NCT00801515 ViiV Healthcare|Pfizer HIV August 2009
    NCT03163277 Giovanni Di Perri|University of Turin, Italy Hiv|Neurocognitive Dysfunction May 15, 2017 Phase 4
    NCT00981773 Imperial College London|Mater Misericordiae University Hospital HIV Infections September 2009 Phase 4
    NCT00098293 ViiV Healthcare|Pfizer HIV-1 November 2004 Phase 3
    NCT00764465 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy October 2008 Phase 2
    NCT01637259 Kirby Institute Proteinuria|HIV June 2012 Phase 4
    NCT01505114 National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network|AIDS Clinical Trials Group HIV Infection June 2012 Phase 2
    NCT00525733 Rockefeller University|Aaron Diamond AIDS Research Center|Merck Sharp & Dohme Corp.|Pfizer HIV Infections October 2007
    NCT00976404 Robert L. Murphy|Objectif Recherche Vaccins SIDA|National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer|Merck Sharp & Dohme Corp.|Northwestern University HIV Infection November 2009 Phase 2
    NCT01400412 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection December 2011 Phase 2
    NCT02741323 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections January 1, 2017 Phase 2
    NCT03218592 University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID) HIV/AIDS June 28, 2017 Phase 4
    NCT00496782 ViiV Healthcare|Pfizer HIV Infections July 2007 Phase 1
    NCT02475915 South East Asia Research Collaboration with Hawaii|The Thai Red Cross AIDS Research Centre|Cooper Human Systems Acute HIV Infection January 2015 Phase 1|Phase 2
    NCT00643643 ViiV Healthcare|Pfizer HIV Infections October 2002 Phase 2
    NCT01033760 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Merck Sharp & Dohme Corp.|Pfizer|Janssen-Cilag Ltd. HIV-1 Infections April 2010 Phase 3
    NCT00977756 International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2002
    NCT02961829 Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|ViiV Healthcare Chronic Infection|HIV July 2015
    NCT02208037 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Hodgkin's Lymphoma August 2014 Phase 2
    NCT00537394 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections January 2008 Phase 3
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 1.9468 mL 9.7339 mL 19.4678 mL
    5 mM 0.3894 mL 1.9468 mL 3.8936 mL
    10 mM 0.1947 mL 0.9734 mL 1.9468 mL
    Kinase Assay
    [1]

    Binding of 125I-labeled MIP-1α, MIP-1β, and RANTES to CCR5 is measured essentially using intact HEK-293 cells stably expressing the receptor or membrane preparations thereof. Briefly, cells are resuspended in binding buffer (50 mM HEPES containing 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin [BSA] and adjusted to pH 7.4) to a density of 2×106 cells/mL. For membrane preparations, phosphate-buffered saline (PBS)-washed cells are resuspended in lysis buffer (20 mM HEPES, 1 mM CaCl2, 1 tablet COMPLETE per 50 mL, pH 7.4; Boehringer) prior to homogenization in a Polytron hand-held homogenizer, ultracentrifugation (40,000× g for 30 min), and resuspension in binding buffer to a protein concentration of 0.25 mg/mL (12.5 μg of membrane protein is used in each well of a 96-well plate). 125I-radiolabeled MIP-1α, MIP-1β, and RANTES are prepared and diluted in binding buffer to a final concentration of 400 pM in the assay. Appropriate maraviroc dilutions are added to each well to a final volume of 100 μL, the assay plates incubated for 1 h, and the contents filtered through preblocked and washed Unifilter plates which are counted following overnight drying[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Maraviroc is prepared in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use[1].

    HEK-293 cell aliquots (100 μL at 1×106 cells/mL) are plated into poly-D-lysine-coated plates and incubated at 37°C overnight. A 1:1 mix of soluble recombinant human CD4 (sCD4) (diluted to 4.5 nM in culture medium) and HIV-1 gp120 is incubated at room temperature for 15 min prior to its addition to PBS-washed cells in the presence of dilutions of maraviroc to enable IC50 determination. The assay plates are incubated at 37°C for 1 h and washed. Eu3+-labeled anti-gp120 antibody (1/500 dilution in assay buffer) is added to each well (50 μL) and incubated for 1 h. The plate is washed three times with wash buffer prior to the addition of enhancement solution (200 μL/well) and measurement of Eu3+ fluorescence (Victor2multilabel counter; “Europium” protocol). Nonspecific binding is taken as the fluorescence measured for gp120 incubated with cells in the absence of preincubation with sCD4[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][2]

    Maraviroc is dissolved in DMSO and then diluted with PBS or saline.

    Rat and Dog[1]
    Preclinical pharmacokinetic studies are carried out with maraviroc following a single intravenous and oral administration to both male Sprague-Dawley rats (1 mg/kg of body weight given intravenously [i.v.] and 10 mg/kg given orally [p.o.]; n=2) and male beagle dogs (0.5 mg/kg i.v. and 2 mg/kg p.o; n=4). Plasma samples are taken for up to 24 h postdose, and the concentrations of unchanged maraviroc are determined using a specific high-performance liquid chromatography-tandem mass spectrum assay.
    Mice[2]
    Splenocytes are collected from 6-10 week old CCR5-/- mice or wild-type controlmice (n=8 per group) and naive CD4+ CD45RBhigh T-cells are isolated by cell sorting. A total of 3×105 CD45RBhigh cells are then injected intravenously into Rag1-/- mice that are subsequently weighed and assessed for fecal score every 20 days to evaluate IBD development. To investigate whether Maraviroc rescues from intestinal inflammation induced by transfer colitis, Rag1-/- mice are injected with CD4+ CD45RB-/- T-cells and 34 days later randomized into either a control group (no further treatment, n=6) or treatment with Maraviroc, 50 mg/kg/d Maraviroc per os (n=4) for 3 weeks, 5 d/week. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    M.Wt

    513.67

    Formula

    C₂₉H₄₁F₂N₅O

    CAS No.

    376348-65-1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Maraviroc
    Cat. No.:
    HY-13004
    Quantity: